Plasma Apelin, Visfatin and Resistin Levels in Patients with First Episode Psychosis and Chronic Schizophrenia

Şahpolat, Musa; Arı, Mustafa; Kokaçya, Mehmet Hanifi

doi:10.9758/cpn.2020.18.1.109

Cited by 22 publications

(17 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immune dysregulations include increased levels of inflammatory markers such as C - reactive protein (CRP), interlukin-6 (IL-6), tumour necrosis factor alpha (TNF alpha), and other cytokines indicating insulin and leptin resistance, obesity, inflammation, and higher rates of metabolic syndrome [ 21 ]. Recent study indicated that plasma apelin level higher among schizophrenia patients which may be related to severity of mental illness which impact on MetS [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia

et al. 2021

View full text Add to dashboard Cite

Background Globally, the prevalence of metabolic syndrome (MetS) is higher among patients with schizophrenia than the general population, and this leads to higher morbidity and mortality in this population. The aim of this study was to investigate the MetS prevalence among patients with schizophrenia in Ethiopia. Methods We conducted a cross-sectional analysis of baseline data of 200 patients with schizophrenia recruited from Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia. Lipid profile and blood glucose levels were measured using Roche Cobas 6000 clinical chemistry analyzer. The prevalence of MetS was assessed based on National Cholesterol Education Program Adult Treatment Panel III criteria. Patients’ demographic information, clinical and laboratory data, lifestyle habits, particularly smoking and Khat chewing, were evaluated vis-à-vis MetS. Results The overall prevalence of MetS in patients with schizophrenia was 21.5% (17.1% male, 29.6% female) where Low HDL-cholesterol value was the most common metabolic disorders components in both males and females subgroups. In the multivariate analysis, the positive and negative symptoms score (PANSS, AOR = 1.03, 95% CI 1.001–1.054) was associated factors with MetS. Conclusion In Ethiopia, patients with schizophrenia were found to have higher prevalence of MetS than the general population. Physicians/health care providers should routinely screen patients with schizophrenia for MetS and initiate timely management of those who develop the syndrome to reduce the health cost from caring for NCDs, improve the patients’ quality of life, and prevent premature mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Numerous proteins and cytokines that are secreted by adipose tissue have been shown to play physiological roles in the human body, including in inflammation, coagulation, vascular remodeling, regulation of blood pressure, lipid metabolism, glucose metabolism, energy balance, and appetite. 30 , 31 These include the adipokines interleukin (IL)-6, tumor necrosis factor (TNF)-α, insulin-like growth factor-1, leptin, resistin, nesfatin 1, apelin, visfatin, and C-reactive protein; and sex hormones. 32 Several previous studies have demonstrated that high circulating concentrations of these substances are present in patients with psychotic disorders, both during the early and later phases.…”

Section: Introductionmentioning

confidence: 99%

“… 32 Several previous studies have demonstrated that high circulating concentrations of these substances are present in patients with psychotic disorders, both during the early and later phases. 30 , 31 , 33 Several types of adipokine receptors have been identified in components of the central nervous system and have been demonstrated to affect brain function. 34 This provides an important link between obesity/MetS and psychotic disorders, namely greater monocyte/macrophage activation and inflammation.…”

Section: Introductionmentioning

confidence: 99%

Metabolic syndrome following a first episode of psychosis: results of a 1-year longitudinal study conducted in metropolitan Lisbon, Portugal

et al. 2022

View full text Add to dashboard Cite

Objective We aimed to assess the prevalence and course of metabolic syndrome (MetS) and the associated metabolic parameters during the year following a first episode pf psychosis (FEP). Methods We performed a 1-year longitudinal observation of 60 patients who experienced FEP. MetS was defined using the modified definition of the National Cholesterol Education Program Adult Treatment Panel III. We assessed the metabolic parameters and socio-demographic and psychopathological data for the participants. Results The mean age of the participants was 27.1 years, and 33.3% of them were women. There was an increase in the prevalence of MetS from 6.7% to 11.7% during the year following the baseline assessment during the year following the baseline assessment ( p = 0.250). There were also significant increases in the prevalences of abnormal triglyceride concentration, waist circumference, and high-density lipoprotein (HDL)-cholesterol concentration during this period. In addition, there was a considerable worsening of the metabolic profile of the participants. No baseline parameters were identified to be predictors of MetS over the 1-year follow-up period. Conclusions We can conclude that metabolic abnormalities are common in patients with FEP and that these rapidly worsen during the first year following the diagnosis of FEP. Studies on interventions are needed to reduce metabolic risk to cardiovascular diseases following the FEP.

show abstract

“… 34 It is known that adipocyte and immune cell dysfunction are involved in the etiology of schizophrenia. 35 , 36 Several studies have shown an elevation of the inflammatory cytokines, chemokines and adipokines in the serum of patients with chronic schizophrenia, which are highly linked to the incidence of disease and metabolic syndrome. 35 , 36 A previous study demonstrated that induced inflammation in WAT was associated with a significant increase in TNFα expression in olanzapine-treated rats.…”

Section: Discussionmentioning

confidence: 99%

“… 35 , 36 Several studies have shown an elevation of the inflammatory cytokines, chemokines and adipokines in the serum of patients with chronic schizophrenia, which are highly linked to the incidence of disease and metabolic syndrome. 35 , 36 A previous study demonstrated that induced inflammation in WAT was associated with a significant increase in TNFα expression in olanzapine-treated rats. 37 However, when we examined the levels of inflammatory mediators, olanzapine decreased TNF-α and MCP-1 expression in WAT.…”

Section: Discussionmentioning

confidence: 99%

Early Lipid Metabolic Effects of the Anti-Psychotic Drug Olanzapine on Weight Gain and the Associated Gene Expression

Chen¹,

Nakano²,

Hsu³

et al. 2022

NDT

View full text Add to dashboard Cite

Background Atypical antipsychotics such as olanzapine often cause metabolic side effects such as obesity and diabetes, leading to an increased risk of nonalcoholic fatty liver disease. The aim of the present study was to investigate the effects of olanzapine treatment on hepatic lipid metabolism and its possible relationship with adipose tissue status. Methods Using a female rat model, we investigated the effects of chronic olanzapine administration on the regulation of carbohydrate and lipid metabolism including lipid biosynthesis, oxidation, efflux, and lipolysis in liver and adipose tissue. Results The body weight, liver mass and visceral adiposity after olanzapine treatment (2 mg/kg) for five weeks were not significantly different compared with vehicle controls. The serum level of triglycerides was higher in the vehicle controls than in olanzapine-treated rats. Unexpectedly, olanzapine treatment did not reduce glucose tolerance in our model. The expression of functional thermogenic protein uncoupling protein 1 (UCP1) was increased in brown adipose tissue (BAT) of the olanzapine group. Additionally, olanzapine treatment also reduced adipose inflammation in white adipose tissue (WAT). The transcription factor sterol regulatory element-binding protein (SREBP)-1c, a key early regulator of lipogenesis, was downregulated following olanzapine treatment. The expression of genes related to the triglycerides synthesis apparatus in the liver was upregulated in the olanzapine group. Olanzapine treatment induced genes involved in PPAR-α signaling and mitochondrial fatty acid oxidation in response to increased ATGL-mediated lipolysis in the liver. Conclusion Together, our findings suggest a complicated link between olanzapine therapy and metabolic disturbance and may garner interest in assessing the action of antipsychotic-induced metabolic disturbances.

show abstract

Plasma Apelin, Visfatin and Resistin Levels in Patients with First Episode Psychosis and Chronic Schizophrenia

Cited by 22 publications

References 49 publications

Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia

Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia

Metabolic syndrome following a first episode of psychosis: results of a 1-year longitudinal study conducted in metropolitan Lisbon, Portugal

Early Lipid Metabolic Effects of the Anti-Psychotic Drug Olanzapine on Weight Gain and the Associated Gene Expression

Contact Info

Product

Resources

About